CN102170898A - 用于辐射暴露治疗的组合物和方法 - Google Patents

用于辐射暴露治疗的组合物和方法 Download PDF

Info

Publication number
CN102170898A
CN102170898A CN2009801387748A CN200980138774A CN102170898A CN 102170898 A CN102170898 A CN 102170898A CN 2009801387748 A CN2009801387748 A CN 2009801387748A CN 200980138774 A CN200980138774 A CN 200980138774A CN 102170898 A CN102170898 A CN 102170898A
Authority
CN
China
Prior art keywords
mdp
radiation
microparticles
microgranule
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801387748A
Other languages
English (en)
Chinese (zh)
Inventor
弗兰克·B·格尔德
吉莲·艾利森·韦伯斯特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innate Therapeutics Ltd
Original Assignee
Innate Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innate Therapeutics Ltd filed Critical Innate Therapeutics Ltd
Publication of CN102170898A publication Critical patent/CN102170898A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05Dipeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/10X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092Details
    • A61N2005/1094Shielding, protecting against radiation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/10X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092Details
    • A61N2005/1098Enhancing the effect of the particle by an injected agent or implanted device
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/10X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CN2009801387748A 2008-09-30 2009-09-30 用于辐射暴露治疗的组合物和方法 Pending CN102170898A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NZ571665A NZ571665A (en) 2008-09-30 2008-09-30 Compositions and methods for treatment of radiation exposure utilising cross-linked muramyl dipeptide microparticles
NZ571665 2008-09-30
PCT/NZ2009/000207 WO2010039048A1 (en) 2008-09-30 2009-09-30 Compositions and methods for treatment of radiation exposure

Publications (1)

Publication Number Publication Date
CN102170898A true CN102170898A (zh) 2011-08-31

Family

ID=42073685

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801387748A Pending CN102170898A (zh) 2008-09-30 2009-09-30 用于辐射暴露治疗的组合物和方法

Country Status (10)

Country Link
US (1) US10232010B2 (https=)
EP (1) EP2349311B1 (https=)
JP (2) JP6053283B2 (https=)
CN (1) CN102170898A (https=)
AU (1) AU2009300442B2 (https=)
BR (1) BRPI0913783A2 (https=)
CA (1) CA2738622C (https=)
ES (1) ES2435438T3 (https=)
NZ (1) NZ571665A (https=)
WO (1) WO2010039048A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108273038A (zh) * 2018-03-16 2018-07-13 中国人民解放军军事科学院军事医学研究院 防治肠型放射病的药物组合物
CN111060697A (zh) * 2019-02-24 2020-04-24 中国疾病预防控制中心辐射防护与核安全医学所 一种利用hmgb1的小肠放射性损伤标记方法

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017059486A1 (en) * 2015-10-06 2017-04-13 Innate Immunotherapeutics Limited Compositions and methods for the treatment of epilepsy
CA2926507A1 (en) * 2015-10-06 2017-04-06 Innate Immunotherapeutics Limited Compositions and methods for protection and/or repair of the nervous system
WO2017070731A1 (en) * 2015-10-28 2017-05-04 Innate Immunotherapeutics Limited Compositions and methods for the treatment of alzheimer's disease
WO2022150763A1 (en) * 2021-01-11 2022-07-14 The George Washington University Nanoparticle-mediated immune cell manufacture and uses thereof
JP2024511277A (ja) 2021-02-19 2024-03-13 メビオン・メディカル・システムズ・インコーポレーテッド 粒子線治療システムのためのガントリー

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1234078A (zh) * 1996-10-10 1999-11-03 探针国际公司 治疗病毒感染的组合物及方法
WO2000024378A1 (en) * 1998-10-23 2000-05-04 Polyheal Ltd Compositions of microspheres for wound healing

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4815446A (en) * 1985-05-09 1989-03-28 Alpha Therapeutic Corporation Process for treating metastasis of cancerous tumors
ATE303160T1 (de) * 1993-08-11 2005-09-15 Jenner Technologies Impfstoff gegen prostatakrebs
GB9320820D0 (en) * 1993-10-08 1993-12-01 Biokine Tech Ltd Compounds for medicinal use
JP5662309B2 (ja) * 2008-04-01 2015-01-28 イネイト・イムノセラピューティクス・リミテッド 腫瘍性疾患を治療するための組成物および方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1234078A (zh) * 1996-10-10 1999-11-03 探针国际公司 治疗病毒感染的组合物及方法
WO2000024378A1 (en) * 1998-10-23 2000-05-04 Polyheal Ltd Compositions of microspheres for wound healing

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
B.B.C.YOUAN: "Protein-loaded poly(e-caprolactone) microparticles.II. Muramyl dipeptide for oral controlled release of adjuvant", 《J. MICROENCAPSULATION》 *
ICHIOR AZUMA: "REVIEW: INDUCER OF CYTOKINES IN VIVO: OVERVIEW OF FIELD AND ROMURTIDE EXPERIENCE", 《INT. J. LMMUNOPHARMAC.》 *
ICHIOR AZUMA: "Synthetic immunoadjuvants:application to non-specific host stimulation and potentiation of vaccine immunogenicity", 《VACCINE》 *
JAROSLAV TURANEK ET AL.: "STIMULATION OF HAEMOPOIESIS AND PROTECTION OF MICE AGAINST RADIATION INJURY BY SYNTHETIC ANALOGUES OF MURAMYLDIPEPTIDE INCORPORATED IN LIPOSOMES", 《INT. J. LMMUNOPHARMAC.》 *
NAVNEET PURI ET AL.: "An investigation of the intradermal route as an e€ective means of immunization for microparticulate vaccine delivery systems", 《VACCINE》 *
钟英英: "天然免疫调节肽的研究概况", 《重庆科技学院学报(自然科学版)》 *
齐子荣: "胞壁酰二肽的生物学作用", 《中国人民解放军军事医学科学院院刊》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108273038A (zh) * 2018-03-16 2018-07-13 中国人民解放军军事科学院军事医学研究院 防治肠型放射病的药物组合物
CN111060697A (zh) * 2019-02-24 2020-04-24 中国疾病预防控制中心辐射防护与核安全医学所 一种利用hmgb1的小肠放射性损伤标记方法

Also Published As

Publication number Publication date
ES2435438T3 (es) 2013-12-19
US10232010B2 (en) 2019-03-19
NZ571665A (en) 2011-01-28
US20110236346A1 (en) 2011-09-29
AU2009300442A1 (en) 2010-04-08
JP6053283B2 (ja) 2016-12-27
JP2012504161A (ja) 2012-02-16
BRPI0913783A2 (pt) 2016-11-01
AU2009300442B2 (en) 2014-03-13
CA2738622C (en) 2016-10-18
EP2349311A4 (en) 2012-07-04
EP2349311B1 (en) 2013-08-21
WO2010039048A1 (en) 2010-04-08
CA2738622A1 (en) 2010-04-08
JP2016026157A (ja) 2016-02-12
EP2349311A1 (en) 2011-08-03

Similar Documents

Publication Publication Date Title
CN102170898A (zh) 用于辐射暴露治疗的组合物和方法
Lawrence Nuclear physics and therapy: preliminary report on a new method for the treatment of leukemia and polycythemia
CN108403658A (zh) 细胞囊泡制剂与低剂量放疗联合在制备抗肿瘤药物中的应用
CN107669692A (zh) Mpla在制备电离辐射致肠道损伤防治药物中的应用
Furuta et al. Rapid rise in FDG uptake in an irradiated human tumour xenograft
JP6150374B2 (ja) 放射線被ばく治療剤及び放射線被ばく治療方法
CN117883423B (zh) 阿托伐醌在抗辐射损伤中的应用
Gupta et al. Amelioration of radiation-induced hematological and biochemical alterations by Alstonia scholaris (a medicinal plant) extract
Rotmensch et al. The development of α-emitting radionuclide lead 212 for the potential treatment of ovarian carcinoma
CN100518817C (zh) 恢复造血功能的治疗剂和组合物及其用途
Wooles et al. Influence of pre-and post-X-irradiation zymosan administration on reticuloendothelial function
Tálas et al. Influence of acute and fractional X-irradiation on induction of interferon in vivo
CN101168047B (zh) 具有防辐射、抗氧化以及保护dna作用的组合物及用途
CN118384261B (zh) δ-T3HP及其联用rhTPO作为辐射防护剂的医药用途
Srinivasan et al. High-dose antibiotic therapy is superior to a 3-drug combination of prostanoids and lipid A derivative in protecting irradiated canines
CN120114623B (zh) 一种放射性核素标记的具有辐射增敏的纳米联合治疗剂及其制备方法和应用
Rojas et al. Effects of radiomodifiers on high and low LET responses in vivo
CN121466310A (zh) 雌激素类药物和dmso联合在制备抗辐射损伤药物中的应用
CN101168045A (zh) 海洋蛋白肽作为制备防辐射药物、保健食品或食品的用途
Milas et al. Enhancement of lung colony formation by admixing irradiated with viable tumor cells: dependence on host status
CN108904479A (zh) 二烯丙基一硫在制备辐射引起白细胞减少的药物中的应用
CN119564713A (zh) 松果菊苷在制备预防或治疗辐射损伤的药物中的用途
GUENNOUN et al. infection and haemorrhage susceptibility. It can
Gal et al. The Effect of X-Radiation on Reticulo-Endothelial System and its Treatment with Radiodetoxified Endotoxin and Trace Elements in Rats
Harris et al. The response of rabbit spleen explants to ionizing radiation

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110831